Nestle is launching a new frozen-food brand, Vital Pursuit, aimed at the growing market of consumers who are using GLP-1 drugs like Ozempic and Wegovy. Nestle already owns Lean Cuisine, which was founded in 1981 as a healthier alternative to other frozen meals. But the company chose to create a new brand to reach GLP-1 users because Lean's branding focuses on consumers looking to limit their calories. But people who take GLP-1 medications may want to consume more nutrients, like protein, which can help with ...

We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. About this content About William Farrington William kickstarted hi ...

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday. The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage. GLP-1s work by mimicking a hormone produced in the gut to tamp down a person's appetite and regulate their blood sugar. When those medications are in shortage, cert ...

Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p<0.01) and liver triglycerides by 67% (p<0.0001) compared to placebo two months after administration Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein (LDL) cholesterol (both, p<0.0001) compared to placebo two months after administration New results highlight potential for profound, durable, and broad metabolic benefit that can be achieved from single-admi ...

Could Amgen be the next stock to soar due to a GLP-1 drug? Glucagon-like peptide 1 (GLP-1) weight-loss drugs such as Zepbound and Wegovy are growing in popularity. And that has made the companies who make those drugs, Eli Lilly and Novo Nordisk, hot investments over the past few years. But there could soon be many more options out there for patients. Given the potential for a weight-loss drug to generate tens of billions of dollars in revenue for a company, there's bound to be a lot of interest in the space ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32593 Global Partners LP (Exact name of registrant as specified in its charter) Delaware 74-3140887 (State or ot ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Gregory B. Hanson Sean T. Geary Chief Financial Officer Chief Legal Officer and Secretary Global Partners LP Global Partners LP (781) 894-8800 (781) 894-8800 Global Partners LP Reports First-Quarter 2024 Financial Results Waltham, Mass., May 8, 2024 – Global Partners LP (NYSE: GLP) ("Global" or the "Partnership") today reported financial results for the first quarter ended March 31, 2024. CEO Commentary Eric Slifka, the Partnership's President and Chief Executive ...

Global Partners LP (GLP) is set to release first-quarter results on May 8. The current Zacks Consensus Estimate for the to-be-reported quarter is a profit of 10 cents per unit on revenues of $5.2 billion.Let’s delve into the factors that might have influenced the vertically integrated energy partnership’s results in the March quarter. But it’s worth taking a look at GLP’s previous-quarter performance first.Highlights of Q4 Earnings & Surprise HistoryIn the last reported quarter, the Waltham, MA-based gasoli ...

In the latest trading session, Global Partners LP (GLP) closed at $47.33, marking a +1.39% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.46%. Elsewhere, the Dow lost 0.98%, while the tech-heavy Nasdaq lost 0.64%.Shares of the company have appreciated by 4.92% over the course of the past month, outperforming the Oils-Energy sector's gain of 4.21% and the S&P 500's loss of 3.04%.Analysts and investors alike will be keeping a close eye on the performance of Glob ...

Despite the remarkable performance of the Oil/Energy market so far this year — up 16.6% compared with the S&P 500’s 8.2% increase — not all stocks have become overpriced. There are still plenty of opportunities available. Investors who focus on value aim to identify stocks that are currently undervalued, anticipating that others will eventually recognize their true worth, potentially leading to significant returns. After all, everyone appreciates a good bargain.For those investors seeking stocks with reason ...